Daver N, Jonas BA, Medeiros BC, Patil U, et al. Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Leuk Lymphoma 2022 Jul 14:1-4. doi: 10.1080/10428194.2022.2092853.
PMID: 35834732